生物来源
mouse
质量水平
抗体形式
purified antibody
抗体产品类型
primary antibodies
克隆
24-21, monoclonal
表单
liquid
包含
≤0.1% sodium azide as preservative
种属反应性
mouse, human
制造商/商品名称
Calbiochem®
储存条件
do not freeze
dilution
(Immunoblotting (1-5 µg/mL)
Immunofluorescence
Immunoprecipitation (1-2 µg/sample)
Neutralization Studies (not recommended))
同位素/亚型
IgG1
运输
wet ice
储存温度
2-8°C
靶向翻译后修饰
unmodified
基因信息
human ... ABL1(25)
一般描述
Anti-c-Abl (Ab-3), mouse monoclonal, clone 24-21, recognizes the ~145 kDa human and ~150 kDa mouse c-Abl. It is validated for Western blotting, immunofluorescence, and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with p.3U1 mouse myeloma cells (see application references). Recognizes the v-Abl, the ~145-150 kDa c-Abl, the ~210 kDa Bcr-Abl (CML), and the ~190 kDa Bcr-Abl (ALL) proteins.
Recognizes the ~145 kDa human c-Abl, the ~150 kDa mouse c-Abl, v-Abl, and the Bcr/Abl translocation products in ALL (~190 kDa) and CML (~210 kDa). Does not inhibit protein tyrosine kinase activity.Antibody Target Gene Symbol: ABL1 Target Synonym: ABL, AI325092, bcr/abl, C-ABL, C-ABL 1B, CABL1, E430008G22Rik, JTK7, MGC117749, p145Abl, p150, v-abl Entrez Gene Name: c-abl oncogene 1, receptor tyrosine kinase Hu Entrez ID: 25 (Related Antibodies: PK1006PK1013OP19) Mu Entrez ID: 11350 Rat Entrez ID: 311860
免疫原
a recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE
应用
Immunoblotting (1-5 µg/ml)
Immunofluorescence (see application references)
Immunoprecipitation (1-2 µg/sample)
Neutralization Studies (not recommended)
Immunofluorescence (see application references)
Immunoprecipitation (1-2 µg/sample)
Neutralization Studies (not recommended)
包装
Please refer to vial label for lot-specific concentration.
外形
In 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.
分析说明
Positive Control
K562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
K562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
其他说明
Does not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
Wiedemann, L.M., et al. 1988. Blood71, 349.
Stam, K., et al. 1985. N. Engl. J. Med.313, 1429.
Konopka, J.B., et al. 1984. Cell37, 1035.
Prywes, R., et al. 1983. Cell34, 569.
de Klein, A., et al. 1982. Nature300, 765.
Reynolds, F.H., Jr., et al. 1980. J. Virol.36, 374.
Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA75, 3974.
Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA75, 2488.
Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res.30, 2213.
Stam, K., et al. 1985. N. Engl. J. Med.313, 1429.
Konopka, J.B., et al. 1984. Cell37, 1035.
Prywes, R., et al. 1983. Cell34, 569.
de Klein, A., et al. 1982. Nature300, 765.
Reynolds, F.H., Jr., et al. 1980. J. Virol.36, 374.
Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA75, 3974.
Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA75, 2488.
Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res.30, 2213.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Toxicity: Standard Handling (A)
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
nwg
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Tamjeed Saleh et al.
Nature structural & molecular biology, 24(11), 893-901 (2017-09-26)
The activity of protein kinases is often regulated in an intramolecular fashion by signaling domains, which feature several phosphorylation or protein-docking sites. How kinases integrate such distinct binding and signaling events to regulate their activities is unclear, especially in quantitative
Cong Fang et al.
Cancer research, 70(21), 8299-8308 (2010-09-15)
Oncogenic kinase activity and the resulting aberrant growth and survival signaling are a common driving force of cancer. Accordingly, many successful molecularly targeted anticancer therapeutics are directed at inhibiting kinase activity. To assess kinase activity in minute patient samples, we
Alexander J M Blakes et al.
European journal of human genetics : EJHG, 29(4), 593-603 (2020-11-24)
ABL1 is a proto-oncogene encoding a nonreceptor tyrosine kinase, best known in the somatic BCR-ABL fusion gene associated with chronic myeloid leukaemia. Recently, germline missense variants in ABL1 have been found to cause an autosomal dominant developmental syndrome with congenital
Martin Frejno et al.
Molecular systems biology, 13(11), 951-951 (2017-11-05)
Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models for proteome-guided pre-clinical drug sensitivity studies are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC)
Jennifer Asmussen et al.
Cancer discovery, 4(2), 200-215 (2013-12-24)
The clinical experience with BCR-ABL tyrosine kinase inhibitors (TKI) for the treatment of chronic myelogenous leukemia (CML) provides compelling evidence for oncogene addiction. Yet, the molecular basis of oncogene addiction remains elusive. Through unbiased quantitative phosphoproteomic analyses of CML cells
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持